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Summary
BACKGROUND: Preventive treatment may avoid future
cases of tuberculosis among asylum seekers. The effective-
ness of preventive treatment depends in large part on treat-
ment completion.
METHODS: In a prospective cohort study, asylum seekers
of two of the Swiss Canton Vaud migration centres were
screened with the Interferon Gamma Release Assay
(IGRA). Those with a positive IGRA were referred for
medical examination. Individuals with active or past tuber-
culosis were excluded. Preventive treatment was offered
to all participants with positive IGRA but without active
tuberculosis. The adherence was assessed during monthly
follow-up.
RESULTS: From a population of 393 adult migrants, 98
(24.9%) had a positive IGRA. Eleven did not attend the ini-
tial medical assessment. Of the 87 examined, eight presen-
ted with pulmonary disease (five of them received a full
course of antituberculous therapy), two had a history of pri-
or tuberculosis treatment and two had contraindications to
treatment. Preventive treatment was offered to 75 individu-
als (4 months rifampicin in 74 and 9 months isoniazid in
one), of whom 60 (80%) completed the treatment.
CONCLUSIONS: The vulnerability and the volatility of
this population make screening and observance of treat-
ment difficult. It seems possible to obtain a high rate of
completion using a short course of treatment in a closely
monitored population living in stable housing conditions.
Key words: rifampicin; tuberculosis; asylum seekers;
LTBI; preventive treatment
Introduction
Latent tuberculosis infection (LTBI) is a widespread con-
dition among asylum seekers born in or who have lived in
countries with a high prevalence of tuberculosis [1]. Per-
sons with LTBI have a known risk of developing active
tuberculosis at a later stage [2] and can be screened by
tuberculin skin testing or by one of the new Interferon
Gamma Release Assays (IGRA), which offer a greater spe-
cificity [3]. Among the persons with positive IGRA, those
most at risk of developing an active infection are children,
immunosuppressed persons and those with recently ac-
quired infection. The highest risk for the development of
tuberculosis among infected persons is during the first few
years following infection. The risk of reactivation, defined
as the progression from latent infection to active disease
can be decreased by preventive treatment [4].
Asylum seekers (AS) from high incidence countries en-
tering in low incidence countries have a higher rate of
LTBI than the local population, therefore some of them
may develop TB after entering the country, by reactivation
from remote infection. In some low incidence countries
AS or migrants are screened for active TB and LTBI upon
entry. In Switzerland AS are screened at the border for act-
ive TB only. Cases with LTBI are not detected and not
offered a preventive treatment so that the possible progres-
sion from infection to disease after entry is not preven-
ted. The treatment of latent tuberculosis infection (LTBI) is
generally considered costeffective and a component of the
strategy towards elimination of tuberculosis in low-incid-
ence countries [5–7]. The key features of a cost effective
LTBI screening strategy are proper screening, selection of
persons at highest risk of progression and the completion
of preventive treatment by eligible persons with LTBI who
are expected to follow a long treatment in spite of being
asymptomatic [8].
The low adherence to LTBI treatment is the main challenge
in the preventive strategy. According to various studies the
completion rate of preventive treatment varies from 10%
to 86% [9, 10]. The duration and side effects of preventive
treatment along with the lack of awareness on active tuber-
culosis disease by people with LTBI, and the high social
and economical vulnerability of some population groups
like asylum seekers render adherence to treatment a highly
challenging issue for both the physician and the patient.
No factor seems to reliably predict the adherence to pre-
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ventive treatment [11]. Our study aims to assess the rate
and conditions of adherence to preventive treatment in a
population of asylum seekers with latent tuberculosis infec-
tion recently arrived in Canton Vaud. All aspects regarding
screening results, demography and treatment decision were
described in a separate paper [12].
Methods
We conducted a prospective cohort study to assess the feas-
ibility and adherence of preventive treatment in a popula-
tion of asylum seekers (AS) with LTBI newly arrived in
the Swiss Canton Vaud, who had recently passed a border
screening for the detection of active TB. The AS resided in
two migrant centres at Sainte – Croix and Crissier. AS aged
over 16 years were offered a free IGRA screening for LTBI
by T-SPOT.TB (Oxford Immunotec, Abingdon, UK). All
asylum seekers received written information about tubercu-
losis and the aims of the study were translated into five ma-
jor languages (English, French, German, Russian and Ar-
abic). All participants signed a consent form. A translator
was used if needed. The study was approved by the ethics
commission of the University of Lausanne.
The results of IGRAs were categorised as positive, inde-
terminate or negative. An additional SPOT.TB was offered
to AS with an indeterminate result.
AS with a positive test result were referred for further ex-
amination to a physician for the exclusion of active TB
and a decision on preventive treatment. The physician ob-
tained a detailed history of TB exposure or treatment, and
performed a clinical examination. A chest X-ray was taken
and human immunodeficiency virus (HIV) screening was
offered to the IGRA positive participants. AS with suspect
clinical manifestations or abnormal radiological findings
had further investigations including sputum examination.
AS with documented or possible active tuberculosis were
treated according to the current Swiss guidelines [13].
AS with LTBI without evidence of active disease were
offered a preventive treatment according to the current
Swiss recommendation with four months of rifampicin
(first choice) or nine months of isoniazid. The rifampicin
scheme was preferred over the isoniazid because of its sim-
plicity of prescription (no need for vitamin substitution,
short treatment time) and follow up (better tolerance, no
need for routine liver function test assessment, visible urine
colouration) advantages that could enhance compliance
with treatment [6]. We did not use incentives. Adherence
to treatment was evaluated during the monthly visit to
the physician where clinical examination, side effects and
symptom assessment was performed. If normal, the pre-
ventive treatment prescription was renewed. In cases of ab-
normality, blood tests were requested. The treatment was
self-administered but the nurse in charge of the centre met
regularly (if possible daily) with the treated AS and rein-
forced the treatment instructions. If the physician was not
assured of the adherence to the treatment directly observed
treatment (DOT) for a month was prescribed.
The adherence to treatment was considered as satisfactory
if the AS were compliant with all scheduled visits and
asked for a repeat prescription. No tablet count was per-
formed. Individuals who did not attend two of the sched-
uled appointments were considered as non-adherent. The
treatment was suspended in individuals with poor or prob-
lematic adherence.
Results
The screening assay with T-SPOT.TB among 393 adult AS
living in two asylum seeker centres in Canton Vaud re-
vealed positive IGRA results in 98 (24.9%), who were re-
ferred for further medical examination. The mean age of
the AS with LTBI was 27.63 years. 74% were men, 66%
were Africans, and 17% were Asians. Balkanic and former
Soviet Union nationals were both 8% and 8% of the col-
lective. No AS with LTBI had a known immunosuppress-
ive treatment or condition, notably HIV infection.
Of them, 11 did not attend the first scheduled medical eval-
uation. After examination, documented or possible tuber-
culosis or another pulmonary disease was discovered in
8/87 AS (of whom 5 were prescribed an antituberculosis
treatment). Two other patients had a history of prior treat-
ment for active tuberculosis. Of the 77 IGRA positive
asymptomatic individuals with normal chest X-ray, 2 had
counter indications (severe liver disorder and pregnancy)
for preventive treatment (fig. 1).
An LTBI treatment with daily rifampicin for four months
was offered to 74 AS, one received isoniazid for 9 months
due to counter indication to rifampicin. During the follow
up three participants defaulted on the first follow-up visit,
three on the second and seven on the third (total 13 cases).
In two individuals preventive treatment was suspended be-
cause of poor compliance and substance abuse. During the
follow-up, no serious adverse event was observed and no
treatment was interrupted for medical reasons. The final
rate of completion of preventive treatment in our cohort
was 80% (60/75) (fig. 2).
Figure 1
Preventive treatment completion flowchart.
* IGRA = Interferon Gamma Release Assay
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Discussion
In this prospective study, the rate of adherence to LTBI pre-
ventive treatment in AS was high with 80%.
One particular feature of the migrant population is the young
mean age, allowing the assumption that many persons with
LTBI must have been infected recently and are therefore still
in a period with a high risk of reactivation. One argument for
this is the fact that migrants arriving in Switzerland by land
or sea/ land travel had a higher rate of LTBI than migrants
travelling by air, indicating that travel conditions were a risk
factor for TB exposure and recent infection (data in a sep-
arate publication) [12]. An indication for this is the fact that
about 75% of all TB observed in AS in Switzerland occurs
more than three months after the border screening, probably
by progression from a recent infection in young adults.
Variable rates of completion are reported with partially
contradictory conclusions regarding the risk factors for
non-adherence. A recent study by Horsburgh et al. reported
that 93.7% of contacts of patients with contagious TB ac-
cept the treatment, whereas only 48.3% of health-care
workers with LTBI detected by routine screening accept it
[9]. A study conducted in Arkansas, US, among patients
treated with isoniazid for LTBI found no correlation
between adherence and age, diagnosis, mode of administra-
tion and duration of treatment, but demonstrated that edu-
cation at the first visit could improve the adherence rate for
further treatment [11]. An analysis conducted by Hirsch-
Moverman et al. in the US and Canada reported rates of
completion from 35% to 64% among contacts with TB,
32% to 61% in prisoners and jail inmates, 22% to 90%
among foreign-born persons, with better rates among re-
cent migrants [10]. Reduction of treatment duration from
six or nine months isoniazid to four months rifampicin was
followed by an increase in the completion rate up to 91%.
Another study by the same group reported a progressive
increase of the completion rate from 37% in 1996–1999
to 56.1% in 2002–2005 with tighter follow-up of patients
[14]. Trajman et al. confirmed that the overall completion
rate was satisfactory (73%) but that the reduction of the
treatment duration to four months improved the rate of
completion [15]. Similar conclusions were made in a Swiss
study comparing the tolerance and rate of completion in
contacts with LTBI treated with isoniazid for six months
or rifampicin for four months, where the rate of treatment
Figure 2
Monthly assessment and drop outs.
T spot+: Positive T-SPOT.TB, To: initial examination of the
participants, 4R or 9H: Preventive treatment start either four
months of rifampicin or nine months of isoniazid.
interruption because of liver toxicity decreased from 6.1%
to 2% and the rate of treatment completion increased from
74% to 83% [16].
On the contrary, a prospective study conducted in Boston
in 2006 reported a rate of completion of 28.6% (or 33.3%
in recent contacts) [17]. In one study in South Africa, only
20% of children less than five years exposed to parents
with TB completed the preventive treatment [18].
In Switzerland, the results varied. In a study of asylum
seekers screened at the border with tuberculin skin test,
where the subjects with a positive test result were supposed
to have a medical examination and a prescription of pre-
ventive treatment, a large proportion were not prescribed a
treatment or did not complete it [19]. Other reports were
more favourable. A study conducted at the TB Dispensary
in Lausanne reported a global completion rate of 76%
among persons with a positive tuberculin skin test pre-
scribed a preventive treatment with isoniazid for six
months (70% among foreign-born persons, 93% among
foreign workers and 90% in the local population) [20].
Several studies have reported a higher adherence and a
lower rate of adverse events in subjects with LTBI who
were prescribed a short treatment (four months of rifampi-
cin) than among those who had to take a long treatment
(six to nine months of isoniazid) [21, 22]. A report from
the Centre Antituberculeux in Geneva reported an accept-
ance rate of 83% and a completion rate of 67% among
the patients (mostly contacts of TB cases) who started the
treatment with four months of rifampicin [23]. In under-
served population groups, the results are less favourable.
In a study of undocumented migrants in Lausanne, 10/22
persons with a positive IGRA test accepted the preventive
treatment but only 5 completed it [24].
Not prescribing the preventive treatment in infected persons
with a high risk of progression to active tuberculosis can be
considered as a missed opportunity of reducing the pool of
future cases of disease and the transmission of mycobacter-
ia to contacts [25]. In a recent survey in the Netherlands, the
risk of progression to TB among migrants with a positive
IGRA was between 386 and 590/100,000, depending on the
incidence rate in the country of origin [26].
Our study has some limitations. The screening and accept-
ance of preventive treatment for LTBI was voluntary. 39% of
the AS were not screened and some of them may have been
infected and at risk for progression to active tuberculosis dis-
ease [26]. Considering the fact that the screening was offered
to all participants but that this population was extremely mo-
bile, some staying for only few days in the centre, we con-
sider that this pilot study was representative of the target
population. Furthermore, AS were clearly informed that ac-
ceptance or refusal of the proposed screening and preventive
treatment would have no impact on the final decision regard-
ing granting refugee status or not. Also, although the effic-
acy of rifampicin is less extensively documented than iso-
niazid, because of the enhanced adherence to this preventive
treatment scheme this option is a recommended alternative
to the classical isoniazid scheme [16, 27].
Future uncertainties, difficulties of integration and in com-
munication associated with a divergent representation of
health and disease compared with locals are some of the
problems AS need to overcome. The reasons for the high
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rate of completion of LTBI treatment in this population
of migrants in spite of social, economical and legal prob-
lems are probably related to the selection of a well-toler-
ated short treatment schedule ( four instead of six or nine
months), a stable environment (accommodation in a shel-
ter with dedicated social workers and nurses caring for in-
mates), regular assessment of the drug intake by the nurses,
close coordination with the medical staff of the referral
hospitals and repeated information about the importance of
treatment). This study demonstrates that a policy of screen-
ing for LTBI and preventive treatment can be implemented
in a migrant population with a high rate of adherence if all
obstacles are carefully considered in advance.
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Figures (large format)
Figure 1
Preventive treatment completion flowchart.
* IGRA = Interferon Gamma Release Assay
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Figure 2
Monthly assessment and drop outs.
T spot+: Positive T-SPOT.TB, To: initial examination of the participants, 4R or 9H: Preventive treatment start either four months of rifampicin or
nine months of isoniazid.
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